Crossmark

A case of multiple hepatocellular carcinoma experiencing complete responses to sorafenib and atezolizumab–bevacizumab and developing severe, refractory venous congestive cutaneous ulcers on either regimen

Crossref DOI link: https://doi.org/10.1007/s12328-023-01756-3

Published Online: 2023-01-09

Published Print: 2023-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hayashi, Yorihito

Kaneko, Rena https://orcid.org/0000-0002-0044-1821
Ogino, Hiroki

Uekusa, Toshimasa

Kitajima, Mayako

Ikehara, Takashi

Nagai, Hidenari

Matsuda, Takahisa
Funding

Funding for this research was provided by:

Research Funds to Promote Hospital Functions Provided by the Japan Organization of Occupational Health and Safety.
License Information

Text and Data Mining valid from 2023-01-09

Version of Record valid from 2023-01-09
More Information

Article History

Received: 8 October 2022

Accepted: 3 January 2023

First Online: 9 January 2023

Declarations

:

: The authors have no financial conflicts of interest to disclose.

: All procedure followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

: This study does not contain identifying information of the patients.

Document is current

Any future updates will be listed below